Category
January 2, 2020
Gail E Tomlinson 1 Abstract The cytogenetics of hepatoblastoma demonstrate recurring events which include whole chromosome trisomies, most commonly trisomy of chromosome 2, 8, or 10. In addition, unbalanced translocations involving a breakpoint on the proximal short arm of chromosome 1 are observed which results in a duplication of the long arm of chromosome 1q. The […]
January 1, 2020
Adam Kosti, Liqin Du, Haridha Shivram, Mei Qiao, Suzanne Burns, Juan Gabriel Garcia, Alexander Pertsemlidis, Vishwanath R Iyer, Erzsebet Kokovay, Luiz OF Penalva 13-Cis-retinoic acid (RA) is typically used in postremission maintenance therapy in patients with neuroblastoma. However, side effects and recurrence are often observed. We investigated the use of miRNAs as a strategy to […]
January 1, 2020
Choudhary Saket, Suzanne C Burns, Mirsafian Hoda, Wenzheng Li, Dat T Vo, Qiao Mei, Lei Xiufen, Andrew D Smith, Luiz O Penalva High-dose radiation is the main component of glioblastoma therapy. Unfortunately, radio-resistance is a common problem and a major contributor to tumor relapse. Understanding the molecular mechanisms driving response to radiation is critical for […]
January 1, 2020
Sajina Shakya, Anthony D Gromovsky, James S Hale, Arnon M Knudsen, Briana Prager, Lisa C Wallace, Luiz OF Penalva, Pavlina Ivanova, H Alex Brown, Bjarne W Kristensen, Jeremy N Rich, Justin D Lathia, J Mark Brown, Christopher G Hubert Background: Glioblastoma (GBM) is marked by cellular heterogeneity, including metabolic heterogeneity, that varies among cellular microenvironments […]
December 30, 2019
Li-Ju Wang, Catherine W. Zhang, Sophia C. Su, Hung-I H. Chen, Yu-Chiao Chiu, Zhao Lai, Hakim Bouamar, Amelie G. Ramirez, Francisco G. Cigarroa, Lu-Zhe Sun & Yidong Chen Abstract Background Europeans and American Indians were the major genetic ancestry of Hispanics in the U.S. These ancestral groups have markedly different incidence rates and outcomes in many types of cancers. Therefore, the genetic admixture may cause a […]
December 24, 2019
Yiliao Luo Mengxing Li Uday P. Pratap Suryavathi Viswanadhapalli Junhao Liu Prabhakar P. Venkata Kristin A. Altwegg Bridgitte E. Palacios Xiaonan Li Yihong Chen Manjeet K. Rao Andrew J. Brenner Gangadhara R. Sareddy Ratna K. Vadlamud Abstract Medulloblastoma (MB) is the most common and deadliest brain tumor in children. Proline‐, glutamic acid‐, and leucine‐rich protein […]
December 17, 2019
The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been toxic in both preclinical and clinical testing, necessitating TMZ dose reduction to ~15% of the single-agent maximum tolerated dose. We […]
December 9, 2019
UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of leukemia and lymphoma in adults and children. The journal Nature Medicine reported the findings Dec. 2. “This is a new class of drugs called PROTACs that target […]
December 8, 2019
Yu-Chiao Chiu, Hung-I Harry Chen, Aparna Gorthi, Milad Mostavi, Siyuan Zheng, Yufei Huang, Yidong Chen Abstract The recent accumulation of cancer genomic data provides an opportunity to understand how a tumor’s genomic characteristics can affect its responses to drugs. This field, called pharmacogenomics, is a key area in the development of precision oncology. Deep learning (DL) methodology has emerged as a […]